Vertex Pharmaceuticals Inc (VRTX)
Mexican Exchange · Mexico · prices in MXN · close of 22 Oct 2026
Key indicators
| Last close | MXN 10,032.00 |
|---|---|
| 52-week range | 7,300.00 – 10,032.00 |
| Return, 1 month / 3 months | +11.5% / +20.1% |
| Return, 1 year / 3 years | +30.3% / +48.9% |
| Trend | Uptrend |
| RSI (14) | 70 |
| Volatility (1 year) | 26.9% |
| Worst drawdown (1 year) | -16.3% |
| Average daily value traded | 1.70M MXN |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Vertex Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts, that discovers, develops and commercialises medicines for serious diseases. Its main business is treatments for cystic fibrosis, a genetic condition affecting the lungs and other organs, and it supplies these therapies to patients and clinicians in many countries. The company also works on medicines for other conditions, including pain and kidney disease, through its own research and development.
Vertex Pharmaceuticals Inc trades under the code VRTX on the Mexican Exchange in Mexico, with its price quoted in Mexican pesos (MXN). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Vertex Pharmaceuticals Inc (VRTX) trades on the Mexican Exchange in Mexico. It last closed at MXN 10,032.00 on 22 October 2026.
Its price-based Market X-Ray is 72 out of 100 (a strong price profile), ranking 21 of 361 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 30.3% and over the last three months it rose 20.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Mexican Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 86 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 21.2% | ||
| From 52-week high | 0.0% | ||
| Momentum | 80 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 20.1% | ||
| 6-month return | 32.3% | ||
| 12-month return, skipping the last month | 16.9% | ||
| Stability (higher is calmer) | 66 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 26.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -16.3% | ||
| Liquidity | 44 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 1.70M MXN | ||
| Zero-volume days | 45.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +5.6% |
|---|---|
| 1 month | +11.5% |
| 3 months | +20.1% |
| 6 months | +32.3% |
| 1 year | +30.3% |
| 3 years | +48.9% |
| 5 years | +170.6% |
Signals
| 50-day / 200-day average | 9,066.31 / 8,274.25 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 165.14 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Mexican Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.